These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 105227)

  • 1. Acute leukemia following prolonged cytotoxic agent therapy.
    Casciato DA; Scott JL
    Medicine (Baltimore); 1979 Jan; 58(1):32-47. PubMed ID: 105227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer and secondary leukemia.
    Rosner F
    Bull Cancer; 1983; 70(1):55-60. PubMed ID: 6573207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of leukemia following treatment for non-Hodgkin's lymphoma.
    Travis LB; Curtis RE; Stovall M; Holowaty EJ; van Leeuwen FE; Glimelius B; Lynch CF; Hagenbeek A; Li CY; Banks PM
    J Natl Cancer Inst; 1994 Oct; 86(19):1450-7. PubMed ID: 8089863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute leukemia after alkylating-agent therapy of ovarian cancer.
    Reimer RR; Hoover R; Fraumeni JF; Young RC
    N Engl J Med; 1977 Jul; 297(4):177-81. PubMed ID: 406560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute nonlymphocytic leukemia: a delayed complication of Hodgkin's disease therapy: analysis of 109 cases.
    Cadman EC; Capizzi RL; Bertino JR
    Cancer; 1977 Sep; 40(3):1280-96. PubMed ID: 409479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
    van Leeuwen FE; Chorus AM; van den Belt-Dusebout AW; Hagenbeek A; Noyon R; van Kerkhoff EH; Pinedo HM; Somers R
    J Clin Oncol; 1994 May; 12(5):1063-73. PubMed ID: 8164031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
    Pedersen-Bjergaard J; Ersbøll J; Sørensen HM; Keiding N; Larsen SO; Philip P; Larsen MS; Schultz H; Nissen NI
    Ann Intern Med; 1985 Aug; 103(2):195-200. PubMed ID: 4014901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence of secondary leukemias.
    Leone G; Mele L; Pulsoni A; Equitani F; Pagano L
    Haematologica; 1999 Oct; 84(10):937-45. PubMed ID: 10509043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induced acute non-lymphocytic leukemia following long-term chemotherapy: a study of 20 cases.
    Kapadia SB; Krause JR; Ellis LD; Pan SF; Wald N
    Cancer; 1980 Mar; 45(6):1315-21. PubMed ID: 6928396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.
    Pedersen-Bjergaard J; Specht L; Larsen SO; Ersbøll J; Struck J; Hansen MM; Hansen HH; Nissen NI
    Lancet; 1987 Jul; 2(8550):83-8. PubMed ID: 2885581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myelogenous leukaemia following cytotoxic therapy: five cases and a review.
    Smith AG; Prentice AG; Lucie NP; Browning JD; Dagg JH; Rowan RM
    Q J Med; 1982; 51(202):227-40. PubMed ID: 6955825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second malignancies and chemotherapeutic agents.
    Kyle RA
    Prog Clin Biol Res; 1983; 132E():45-54. PubMed ID: 6417671
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute leukemia after treatment for ovarian cancer. Report of four cases and review of the literature.
    De Gramont A; Remes P; Krulik M; Smadja N; Drolet Y; Donadio D; Louvet C; Brissaud P; Sirinelli A; Dray C
    Oncology; 1986; 43(3):165-72. PubMed ID: 3703462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three cases of secondary leukemia. Clinicopathologic findings.
    Nemoto K; Honma K; Ohnishi Y; Abe M; Abe A
    Acta Pathol Jpn; 1987 May; 37(5):817-30. PubMed ID: 3477055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second malignancies associated with chemotherapeutic agents.
    Kyle RA
    Semin Oncol; 1982 Mar; 9(1):131-42. PubMed ID: 6803361
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of acute erythroleukemia in B-cell immunoproliferative disorders after prolonged therapy with alkylating drugs.
    Cardamone JM; Kimmerle RI; Marshall EY
    Am J Med; 1974 Nov; 57(5):836-42. PubMed ID: 4216270
    [No Abstract]   [Full Text] [Related]  

  • 18. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
    Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S
    Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia following non-Hodgkin's lymphoma: danger of prolonged use of chlorambucil as maintenance therapy.
    Dumont J; Thiery JP; Mazabraud A; Natali JC; Trapet P; Vilcoq JR
    Nouv Rev Fr Hematol (1978); 1980; 22(4):391-404. PubMed ID: 6942388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of acute nonlymphocytic leukaemia (ANLL) in myelomatosis.
    Drivsholm A; Lisse I; Philip P
    Scand J Haematol; 1985 Jul; 35(1):35-7. PubMed ID: 4048861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.